TrialGynecologic oncology2012

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Kimberly K Leslie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.